Oct 31, 2023 / 10:30AM GMT
Operator
Ajanta Pharma, Q2 FY 2024 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions) Please note this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you, and over to you, sir.
Yogesh Agrawal Ajanta Pharma Limited-MD
Thank you. A very good evening and welcome to all of you. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO, Mr. Rajeev Agrawal, our AVP Finance and Investor Relations. So, friends I hope that the results are already there with you. We will take you through the business-wise performance for the Q2 and H1 for the year along with a comparison for the previous year same period.
So our three verticals of business Branded Generics, US Generics and Institution Business in Africa it generated the total revenue of INR1,028 crore against INR938 crore,
Q2 2024 Ajanta Pharma Ltd Earnings Call Transcript
Oct 31, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers